

to form a single general inventive concept under PCT Rule 13.1. Applicant traverses this restriction because it does not appear that the Examiner has issued a “restriction requirement” or has particularly explained why the claims do not relate to a single general inventive concept under PCT Rule 13.1. From Applicant’s reading of the Office Action, it appears that the Examiner is only requiring an election of species and has responded accordingly. Applicant’s response should, in no way, be treated as Applicant’s acceptance that the subject-matter of the instant application is subject to restriction.

The Examiner has identified the species on page 2 (Group A) and page 3 (Group B) of the Office Action and has required the Applicant to elect a single species from each group. Applicant hereby elects species number 2, probes generated as partial libraries as recited in claims 16 and 17, from Group B (see new claim 19). With respect to the species election of Group A, Applicant submits that the election of either item 1 or item 2 of Group A will not change the starting point for the purposes of search and examination. Applicant, therefore, does not believe that a species election between items 1 and 2 of Group A is necessary or proper. Reconsideration and removal of the species election with respect to Group A is respectfully requested. However, to fully comply with the Examiner’s species election, Applicant hereby elects item 1 as the species for search and examination (see new claim 20).

2. Sequence Listing

The Examiner has also indicated that the application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. §1.821(a)(1) and (a)(2). The particular reasons for noncompliance were set forth on the attached Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Applicant has reviewed the Specification and located a single nucleotide sequence, which is required to be listed in a sequence listing. Applicant has amended the Specification accordingly and has attached a paper and CRF copy of the sequence listing hereto. Applicant submits that the CRF copy of the sequence is identical to the paper copy. Reconsideration and removal of the sequence listing is requested.


Favorable action on the claims as elected above is requested.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Leonard Svensson (Reg. No. 30,330) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Leonard R. Svensson, #30,330
P.O. Box 747
Falls Church, VA 22040-0747
(714) 708-8555


LRS/KR
147-201P

Attachment: Paper and CRF Copies of Sequence Listing
Version of the Specification with Markings to Show Changes Made

(Rev. 01/22/01)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on: March 31, 2003
(Date of deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP


(Signature)
March 31, 2003
(Date of Signature)

Version of the Specification with Markings to Show Changes Made

In the Specification:

Please replace the description for “Example 7: Coating of a microtitre plate with protein” on page 17 with the following:

--The surface of a microtitre plate is coated with Gene32, a protein that non-specifically binds single-stranded DNA. After coating the target with this protein, an array of target DNAs can be put onto it. If the array of the target DNAs consists of cDNA, these were primed with oligo-dT (e.g. dTTTTTTTTTTTTT) (SEQ ID NO. 1) in this PCR. [Oligo-dT] Oligo-dT interacts heavily with Gene32. The covalent coupling of the oligo-dT to Gene32 may be achieved by means of photocrosslinking with short UV light ^{29,30}. After this immobilization, a library of probes may be used for [analysing] analyzing the target DNA in the above-described way. Use may also be made of sequence-specific protein/DNA interaction (e.g. GCN4/AP1).—